A severe immune response in patients with coronavirus disease 2019 (COVID-19) can cause a potentially lethal unconstrained inflammatory cytokine storm, known as cytokine release syndrome (CRS). The present study provides an overview of the biology underlying CRS and how targeted inhibition of interleukin (IL)-6 signaling may improve outcomes and the survival of patients suffering from COVID-19. Preliminary clinical results have indicated that antagonism of the IL-6 receptor (IL-6R), including with the FDA-approved humanized monoclonal antibody tocilizumab, can improve the outcomes of patients with severe or critical COVID-19 while maintaining a good safety profile. The available clinical data support the expansion of clinical trials using IL-6R targeting inhibitors for severe and critical COVID-19 treatment.
CITATION STYLE
Chen, J.-J., Zhang, L.-N., Hou, H., Xu, L., & Ji, K. (2020). Interleukin‑6 signaling blockade treatment for cytokine release syndrome in COVID‑19 (Review). Experimental and Therapeutic Medicine, 21(1), 1–1. https://doi.org/10.3892/etm.2020.9456
Mendeley helps you to discover research relevant for your work.